Request a Quote

Cyprotex Highlights - November 2020


Cyprotex recently hosted two webinar series in collaboration with colleagues across the industry; Novartis, Genentech, ApconiX, University of Liverpool and Takeda. These series were popular events and we are now pleased to offer them to watch on demand.

A Focus on Drug Transporters

New Approaches in Toxicology


Our latest publication, co-authored with our colleagues at the EU-ToxRisk consortium, is now available to read: ‘Comparing in vitro human liver models to in vivo human liver using RNA-Seq’, published in the Archives of Toxicology.

The paper covers the work performed to analyse several in vitro liver cell models and compare them to healthy human liver tissue using RNA-sequencing technology. Click on the link below to read more in our blog:

Read the blog

Read the paper

Single strand RNA

Read the latest news from parent company, Evotec:

  • Evotec & Bristol Myers Squibb achieve milestone in neurodegeneration collaboration
  • Mubadala Investment Company & Novo Holdings A/S announce investment in Evotec SE
  • Topas Therapeutics raises € 22 million in Series B financing & appoints Klaus Martin, Ph.D. as new CEO
  • Just - Evotec Biologics receives grant for antibody development for the prevention of COVID-19
  • Eternygen announces the first closing of its Series A2 funding round lead by investor Evotec
  • Introducing the Dorothy Crowfoot Hodgkin Campus: Evotec expands Oxfordshire site into a fully-integrated R&D centre
  • Evotec SE reports results & corporate update for the first nine months of 2020
  • Evotec & STORM Therapeutics leverage INDiGO platform to progress first-in-class clinical oncology candidate
  • Evotec presents progress made in accelerating its co-owned pipeline at Capital Markets Day
  • Evotec announces new drug discovery & development partnership with Rappta Therapeutics focused on innovative oncology target

Read the press releases

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:


Download file